Mammalian intrinsic apoptosis requires activation of the initiator caspase-9, which then cleaves and activates the effector caspases to execute cell killing. The heptameric Apaf-1 apoptosome is indispensable for caspase-9 activation by together forming a holoenzyme. The molecular mechanism of caspase-9 activation remains largely enigmatic. Here, we report the cryoelectron microscopy (cryo-EM) structure of an apoptotic holoenzyme and structureguided biochemical analyses. The caspase recruitment domains (CARDs) of Apaf-1 and caspase-9 assemble in two different ways: a 4:4 complex docks onto the central hub of the apoptosome, and a 2:1 complex binds the periphery of the central hub. The interface between the CARD complex and the central hub is required for caspase-9 activation within the holoenzyme. Unexpectedly, the CARD of free caspase-9 strongly inhibits its proteolytic activity. These structural and biochemical findings demonstrate that the apoptosome activates caspase-9 at least in part through sequestration of the inhibitory CARD domain.
Yini
Mammalian intrinsic apoptosis requires activation of the initiator caspase-9, which then cleaves and activates the effector caspases to execute cell killing. The heptameric Apaf-1 apoptosome is indispensable for caspase-9 activation by together forming a holoenzyme. The molecular mechanism of caspase-9 activation remains largely enigmatic. Here, we report the cryoelectron microscopy (cryo-EM) structure of an apoptotic holoenzyme and structureguided biochemical analyses. The caspase recruitment domains (CARDs) of Apaf-1 and caspase-9 assemble in two different ways: a 4:4 complex docks onto the central hub of the apoptosome, and a 2:1 complex binds the periphery of the central hub. The interface between the CARD complex and the central hub is required for caspase-9 activation within the holoenzyme. Unexpectedly, the CARD of free caspase-9 strongly inhibits its proteolytic activity. These structural and biochemical findings demonstrate that the apoptosome activates caspase-9 at least in part through sequestration of the inhibitory CARD domain.
apoptosome | caspase-9 | holoenzyme | caspase activation | cryo-EM A poptosis, also called programmed cell death, plays an essential role in the development of multicellular organisms and the maintenance of tissue homeostasis (1, 2) . Apoptosis is executed by a number of sequentially activated caspases (3) . Caspases are divided into two classes: initiators and effectors (3) . All caspases are synthesized as inactive zymogens in cells and must undergo proteolytic cleavages to become fully activated. An effector caspase is cleaved and activated by an upstream initiator caspase and is responsible for the cleavage of numerous cellular proteins. An initiator caspase undergoes autocatalytic activation, which depends on a specific multimeric adaptor protein complex.
In most known forms of intrinsic apoptosis, caspase-9 and caspase-3/7 are the initiator and the downstream effector caspases, respectively. The multimeric protein complex required for caspase-9 activation is the assembled heptameric Apaf-1 apoptosome (4). The activation mechanisms of the initiator and effector caspases are quite different. The effector caspases, exemplified by caspase-3, exist as stable homodimers. The activation of caspase-3, usually mediated by activated caspase-9, entails a single proteolytic cleavage between the large and small subunits of caspase-3 (5). In contrast, caspase-9 exists as a monomeric, inactive zymogen in cells. The intrachain cleavage is insufficient for the activation of caspase-9 (6-8). Caspase-9 undergoes autocatalytic cleavages on binding to the apoptosome, but the cleaved caspase-9 is only catalytically activated when bound to the apoptosome, prompting the concept of a caspase-9 holoenzyme (9-11). Despite decades of intense investigation, it remains largely unknown how the oligomeric apoptosome facilitates caspase-9 activation. Most previous studies on caspase-9 activation used artificially engineered caspase-9 and were conducted in the absence of the full-length Apaf-1 apoptosome. These studies show that homodimerization drives caspase-9 activation, and thus suggest a similar mechanism by the apoptosome (12, 13).
The 9.5-Å cryoelectron microscopy (cryo-EM) structure of an apoptosome-caspase-9 complex revealed some EM density lobes that are flexibly attached to the center as well as the periphery of the holoenzyme (14, 15 ). An unspecified number of the CARD domains and a single molecule of the caspase-9 protease domain were thought to be located at the center and the periphery, respectively. Although this information might be crucial for understanding caspase-9 activation, neither the identities of the CARD domains nor their interactions with the apoptosome were identified. The cryo-EM structure of the apoptosome at a nearatomic resolution reveals how the monomeric Apaf-1 assembles into a functional heptameric apoptosome, but the CARD domains exhibit no obvious EM density (16) .
In this manuscript, we report the cryo-EM structure of an intact mammalian apoptosome-caspase-9 holoenzyme at a markedly improved resolution and systematic structure-guided biochemical analyses, which together provide important mechanistic insights into the activation of caspase-9 by the Apaf-1 apoptosome.
Results

EM of the Apoptosome
Holoenzyme. An intact holoenzyme was assembled by incubating the full-length human Apaf-1 (residues 1-1,248) with excess amounts of equine cytochrome c (CytC) and
Significance
As a prototypical initiator caspase, caspase-9 has been rigorously studied for 20 years. Although activation of the caspase-9 zymogen and catalytic activity of the mature caspase-9 both strictly depend on the Apaf-1 apoptosome, the underlying mechanism remains poorly understood. Previous mechanistic studies relied heavily on engineered caspase-9 in the absence of the Apaf-1 apoptosome. In this study, we tackle the problem through structure determination of the Apaf-1 apoptosome bound to caspase-9 and biochemical analysis of caspase-9 activity in the presence of the Apaf-1 apoptosome. The results demonstrate that the Apaf-1 apoptosome activates caspase-9 by two means: suppressing the inhibition mediated by the caspase recruitment domains (CARD) domain and stimulating the catalytic activity of the protease domain. human caspase-9 in the presence of 1 mM dATP. The assembled holoenzyme exhibited excellent solution behavior, as judged by gel filtration (Fig. S1A) . The assembled holoenzyme was imaged under cryo-conditions on an FEI Tecnai Polara microscope, and 2,579 micrographs were collected (Fig. S1B) ; 401,784 particles were autopicked for reference-free 2D classification (Fig. S1C) . After 3D classification, a subset of 240,130 particles was used for image construction, with different regions of the holoenzyme exhibiting vastly different resolution limits (Fig. S2) .
A lobe of compact globular density, present in nearly all particles and similar to that reported previously (14, 15) , is located right above the center of the apoptosome (Figs. S2 and  S3 ). An additional but smaller lobe of sickle-shaped density, present in about 10% of the particles, is found at the edge of the central hub, close to the WD40 repeats. The local resolution in these regions was truncated to ∼18 Å in the published structure of the apoptosome holoenzyme (14, 15) . In our structure, application of local masking strategy for the heptameric apoptosome platform, the globular density above the central hub, and the sickleshaped density at the edge of the central hub led to improved overall resolutions of 4.4, 5.1, and 6.9 Å, respectively (Fig. S3) . The central hub of the apoptosome holoenzyme displays an identical structure as that reported previously (16) .
Identification of the CARD Domains. Apaf-1 sequentially contains a CARD at the N terminus, a nucleotide-binding oligomerization domain, and two β-propellers of seven and eight WD40 repeats at the C terminus. The nucleotide-binding oligomerization domain comprises a nucleotide-binding domain (NBD), a small helical domain, a winged-helix domain, and a large helical domain. Caspase-9 consists of an N-terminal CARD and a protease domain. As previously observed (16), the central hub and the spokes of the apoptosome platform are formed by the nucleotidebinding oligomerization domains and the WD40 repeats, respectively (Fig. 1A) . Eight CARDs are identified in the globular density above the central hub, including a layer of four Apaf-1 CARDs (ApCARDs) docking onto the central hub and a second layer of four caspase-9 CARDs (C9CARDs) on top of the ApCARDs (Fig. 1A) .
The assignment of the central CARD complex was based on the observation that two ApCARDs and one C9CARD form a stable heterotrimeric complex through both type I and type II interfaces (17) (Fig. 1B) . Helices H2 and H3 of ApCARD interact with helices H1 and H4 of C9CARD in the type I interface (18) , whereas the intervening turns between H1 and H2 and between H5 and H6 of ApCARD stack against the turns between H2 and H3 and between H4 and H5 of C9CARD in the type II interface. The centrally located hetero-octameric CARD complex, measuring 75 Å in diameter and 60 Å in height, can be viewed as four overlapping heterotrimeric complexes (Fig. 1C) . For three of the four C9CARDs in the central CARD complex, each interacts with two neighboring ApCARDs through type I and type II interfaces (Fig. 1C) . The fourth C9CARD associates with ApCARD through a type II interface only. Because both types of interface are known to be stable (17) , assembly of the central CARD complex in this fashion maximizes the number of type I and type II interfaces, and hence is thermodynamically most favorable.
At 6.9 Å resolution, the sickle-shaped density at the edge of the central hub allowed identification and docking of two ApCARDs and one C9CARD, which are in perfect registry with the reported heterotrimeric complex (17) (Fig. 1D) . Notably, this density was described as a single protease domain of caspase-9 in the previous holoenzyme structures (14, 15) , as well as in a recent report (19) .
Interactions Involving the CARD Domains. In the central CARD complex, four C9CARDs are located on the upper layer, and only three of the four ApCARDs directly contact the apoptosome platform ( Fig. 2A) . The 5.1-Å resolution is insufficient for accurate assignment of specific interactions involving amino acid side chains in the CARD complex. Despite this caveat, the close proximity of the secondary structural elements between ApCARDs and the central hub allows modeling of potential interactions, which may guide experimental scrutiny of their functional importance.
The interactions between ApCARDs and the central hub of the apoptosome are asymmetric. For two ApCARDs, each uses its N-terminal helix H1 and the C-terminal portion of helix H4 to interact with surface regions of the NBD (Fig. 2B) . Despite variations in the detailed interactions, the surface regions of the NBD contacted by these two ApCARDs are similar. In one case, the N-terminal residues Asp2 and Arg6 may hydrogen bond (H-bond) to Thr112 and Glu116, whereas Lys58 and Lys62 are in close proximity of Gln208 and Asp209 (Fig. 2C , Middle and Right). In the other case, Lys4 may donate H-bonds to Tyr109 and Glu175 (Fig. 2C, Left) . The third ApCARD is placed further away from the central hub and may only make limited contacts to the central hub. The 6.9-Å resolution makes it challenging even to speculate on potential interactions at the edge of the central hub. In the heterotrimeric CARD complex, the N-terminal H1 helix of one ApCARD is in close proximity to an N-terminal helix of the NBD (Fig. S4A ). Polar and/or charged residues on H1, such as Arg6 and Asn7, and those on NBD, such as Gln137, Gln138, and Ser141, may interact with each other through H-bonds (Fig.  S4B) . Similarly, polar and/or charged amino acids from the N termini of helices H1 and H4 in the other ApCARD, including Glu14, Lys18, and Gln50, may contact surface residues in WD1 (Fig. S4C) .
Essential Role of the Central CARD Complex. To examine whether the interactions between the CARD complex and the central hub are functionally important, we introduced specific missense mutations into Apaf-1 that were designed to weaken these interactions but have no effect on formation of the apoptosome. We generated six such Apaf-1 variants, designated M3 through M8, and two control variants, M1 (S141W, K142W, and K144W) and M2 (L173W), that are predicted to have no effect on these interactions (Fig. 3) . These Apaf-1 variants were individually incubated with caspase-9 in the presence of CytC and dATP; the proteolytic activity of caspase-9 was examined using its physiological substrate caspase-3 (C163A) (Fig. 3A) . Free caspase-9 exhibited a low level of the proteolytic activity, which was drastically increased by the WT Apaf-1 apoptosome (lanes 5 and 6). As anticipated, the control variants M1 and M2 stimulated caspase-9 activity to the same level as WT Apaf-1 (lanes 7 and 8) . The M3 variant, in which the mutation D209A targets an amino acid at the interface between the CARD complex and the central hub, also functioned similarly as WT Apaf-1 (lane 9). This observation suggests that a single-point mutation may be insufficient for destabilization of the interface. Supporting this analysis, three variants, M4 (D209K and S211K), M5 (Q208K, D209K, and S211K), and M6 (K58E and K62E), each involving two or more mutations at the interface, led to markedly decreased caspase-9 activity compared with WT Apaf-1 (Fig. 3A, lanes 10-12) .
The Apaf-1 variants M7 (D2R, K4E) and M8 (Y109W, T112W, and E116R) contain two and three mutations, respectively, at the interface, yet both variants appeared to stimulate caspase-9 activity to a similar level as WT Apaf-1 (Fig. 3A, lanes 13 and 14) . To better characterize these variants, we used a more sensitive cleavage assay using the fluorogenic peptide substrate Ac-LEHD-AFC (Fig. 3B) . In contrast to the controls, the variants M7 and M8 only stimulated caspase-9 activity to ∼45-50% of the level by WT Apaf-1. Consistent with results of the other assay (Fig. 3A) , the variants M4, M5, and M6 exhibited severely compromised abilities to stimulate caspase-9 activity (Fig. 3B ). These results demonstrate that interactions between the central CARD complex and the central hub are essential for proper activation of caspase-9.
Mutations in these Apaf-1 variants were designed to selectively affect the interface between the central CARD complex and the central hub, but not the assembly of the apoptosome. To confirm the design, we individually incubated five Apaf-1 variants with CytC in the presence of dATP and applied the mixture to gel filtration (Fig. 3C) . These variants include two controls (M1 and M3) and three loss-of-function variants (M4, M5, and M6). All five Apaf-1 variants retained the same ability as WT Apaf-1 to assemble into the apoptosomes (Fig. 3C) .
Why is the interface between the central CARD complex and the central hub required for caspase-9 activation? One possibility is that compromised interactions may affect the integrity of the apoptosome-caspase-9 holoenzyme. To examine this scenario, we assessed formation of a stable holoenzyme on gel filtration by incubating the assembled apoptosome variants with caspase-9. As anticipated, caspase-9 formed a stable holoenzyme complex with WT Apaf-1 and the two control variants M1 and M3, as judged by comigration of the caspase-9 large subunit with the apoptosome (Fig. 3D) . In contrast, caspase-9 failed to comigrate with the apoptosome assembled by each of the three Apaf-1 variants M4, M5, and M6. These results suggest that the reduced ability by these Apaf-1 variants to activate caspase-9 is likely attributable to a compromised ability to form the apoptosome holoenzyme.
An Inhibitory Role by Caspase-9 CARD. Unlike the effector caspases, caspase-9 contains an N-terminal CARD that is required for its activation. The recruitment of caspase-9 by the Apaf-1 apoptosome strictly depends on their respective CARD domains (18, 20) . Two CARD complexes, one above the central hub and the other at the periphery, are prominently featured in the assembled apoptosome holoenzyme. We suspected a regulatory role by C9CARD in addition to its known function in holoenzyme assembly. Indeed, the isolated protease domain of caspase-9 was previously found to exhibit a higher level of proteolytic activity compared with the full-length caspase-9 (12). To investigate this scenario, we generated two caspase-9 variants: residues 98-416, which no longer contains the C9CARD, and residues 140-416, which only contains the protease domain (Fig. 4A) . Compared with full-length caspase-9, the CARD-deleted variant (residues 98-416) exhibited a markedly increased proteolytic activity toward the physiological substrate caspase-3 (C163A) (Fig. 4A,  lanes 6 and 7) . Removal of the linker sequences in caspase-9 led to an even higher level of activity (lane 8). Similar results were obtained using the fluorogenic peptide substrate Ac-LEHD-AFC, where removal of the CARD increased caspase-9 activity by at least 10-fold (Fig. 4B ). These results demonstrate that the CARD domain of caspase-9 directly inhibits its proteolytic activity. This finding strongly argues that assembly of the CARD complex in the apoptosome holoenzyme may serve to relieve the inhibitory effect of C9CARD.
How does the CARD inhibit the proteolytic activity of the caspase-9 protease domain? One possibility is that, similar to effector caspases, free caspase-9 only has robust proteolytic activity in its homodimeric form, and C9CARD inhibits homodimerization. This hypothesis is particularly attractive because caspase-9 inhibition by the BIR3 domain of XIAP is mediated through heterodimerization that involves the homodimerization interface of caspase-9 (21). To investigate this scenario, we engineered three constitutively homodimeric caspase-9 variants using an established strategy, in which a five-residue β-strand at the homodimeric interface of caspase-3 was grafted onto caspase-9 (22) . The resulting caspase-9 variants, hereafter referred to as DC9, remain mainly as stable homodimers on gel filtration (Fig. 5A) . Compared with WT caspase-9, the full-length DC9 exhibited a much higher level of proteolytic activity toward the physiological substrate caspase-3 (C163A) (Fig. 5B, lanes 7 and  8) or the fluorogenic peptide Ac-LEHD-AFC (Fig. 5C ). In particular, the proteolytic activity of the full-length DC9 is ∼12-fold higher than that of WT caspase-9 in the peptide-based assay (Fig.  5C ), consistent with an inhibitory role of C9CARD in caspase-9 homodimerization.
Intriguingly, compared with the full-length DC9, removal of the CARD in DC9 (residues 98-416) led to a 2.5-fold increase of the proteolytic activity, and further truncation of the linker sequences preceding the protease domain resulted in an additional threefold increase (Fig. 5C ). We speculate that DC9 exists in an equilibrium between a large population of homodimers and a small population of monomers, and the presence of C9CARD and the ensuing linker sequences inhibit homodimerization. This speculation appears to be supported by the appearances of the peaks for the various DC9 variants on gel filtration (Fig. 5A) . Instead of the proposed inhibition of caspase-9 homodimerization, Fig. 3 . The interface between the CARD complex and the central hub of the apoptosome platform is essential for caspase-9 activation. (A) Mutations in Apaf-1 that compromise the interface led to decreased caspase-9 activity. The representative SDS/ PAGE gels shown here contain results of the caspase-9 activity assays. Eight Apaf-1 variants, labeled M1-M8, are used in the assays, and their identities are tabulated below the gels. (B) Examination of caspase-9 activity using the fluorogenic peptide Ac-LEHD-AFC. (C) The Apaf-1 mutations exhibited no effect on formation of the apoptosome. The Apaf-1 variants were individually examined for apoptosome assembly by gel filtration (Left), and the peak fractions were visualized by SDS/PAGE and Coomassie staining (Right). (D) Apaf-1 mutations that led to reduced caspase-9 activity also compromised formation of the holoenzyme. Three Apaf-1 variants (M4, M5, and M6) were individually examined for their abilities to assemble into a holoenzyme with WT caspase-9 by gel filtration (Left), and the peak fractions were visualized (Right). Fig. 4 . The CARD and the linker sequences preceding the protease domain of caspase-9 directly inhibit the catalytic activity of caspase-9. (A) Removal of the CARD and the linker sequences preceding the caspase-9 protease domain led to markedly increased catalytic activities compared with the fulllength, WT caspase-9. The physiological substrate caspase-3 (C163A) was used in the assays. (B) The catalytic activities of the caspase-9 variants were examined using the fluorogenic substrate Ac-LEHD-AFC.
C9CARD may directly inhibit the proteolytic activity through binding to the active site or another region of caspase-9. The above experimental results fail to rule out this possibility.
Incubation of the full-length DC9 with the Apaf-1 apoptosome yielded a sixfold increase of the proteolytic activity. In fact, DC9 (residues 140-416) displayed a higher proteolytic activity toward the substrate Ac-LEHD-AFC than the apoptosome-caspase-9 holoenzyme (Fig. 5C) . Intriguingly, the proteolytic activity of DC9 (residues 140-416) is slightly higher than that of the fulllength DC9 in the presence of the Apaf-1 apoptosome (Fig. 5 B  and C) . This finding demonstrates that the homodimerized protease domain of caspase-9 has a proteolytic activity that is at least comparable to or higher than that of the apoptosome caspase-9 holoenzyme.
Discussion
During our manuscript preparation, we noted publication of a cryo-EM structure of the apoptosome-caspase-9 holoenzyme at considerably improved resolutions over previous studies (19) . The average local resolutions for the apoptosome platform and the globular density above the central hub were reported to be 4.1 and 5.8 Å, respectively (19) . The central globular density was assigned to a 4:4 complex between ApCARD and C9CARD with an identical arrangement as observed in this study. The density lobe at the periphery of the central hub, previously reported to be 18 Å resolution (14, 15) , was again assigned to a single caspase-9 protease domain (19) . In our cryo-EM reconstruction, the average local resolutions for the apoptosome platform, the central globular density, and the sickle-shaped density at the periphery were estimated to be 4.4, 5.0, and 7.0 Å, respectively. These resolution limits allowed us to determine the identity of individual domains and their relative orientations. Different from the published study (19) , the sickle-shaped density at the periphery of the central hub was identified to be a 2:1 complex between ApCARD and C9CARD. This represents a major structural difference.
In this study, we demonstrate that the interface between the central CARD complex and the central hub of the apoptosome platform is essential for caspase-9 activation. Mutations in Apaf-1 that compromise this interface had no effect on apoptosome assembly but crippled caspase-9 recruitment and holoenzyme formation (Fig. 3) . Both the proteolytic assays and the gel filtration runs were performed with a molar ratio of 5:1 for Apaf-1 over caspase-9; the under-stoichiometric amount of caspase-9 proved important for maximizing the difference between WT and mutant Apaf-1 variants.
Given that the isolated ApCARD stably interacts with C9CARD (18), why would mutations not affecting the ApCARD-C9CARD interactions compromise caspase-9 recruitment into the apoptosome? One explanation is that ApCARD in the assembled apoptosome is unavailable to interact with C9CARD alone, and caspase-9 recruitment is coupled to assembly of the octameric CARD complex and its docking onto the central hub. In other words, assembly of the CARD complex and its interaction with the central hub are coupled, and thus both are required to allow caspase-9 recruitment. Under this scenario, compromised interface between the CARD complex and the central hub no longer allows assembly of the CARD complex or recruitment of caspase-9. Why are only four ApCARDs involved in the central CARD complex? The other three ApCARDs from the apoptosome cannot be stacked on top of the 4:4 CARD complex because the length of the linker sequence between the CARD and the NBD (14 residues) is too short.
How does the assembly of the central CARD complex assist caspase-9 activation? We identified the inhibitory role of the CARD in controlling caspase-9 activity (Fig. 4) . The CARD Fig. 5 . CARD-deleted, constitutive homodimeric caspase-9 exhibits a similar level of catalytic activity as the apoptosome-caspase-9 holoenzyme. (A) The engineered caspase-9 with its β6 strand replaced by that of caspase-3 was eluted from gel filtration as a stable homodimer. This is shown for the full-length caspase-9 (DC9), CARD-deleted (residues 98-416), and the protease domain alone (residues 140-416). (B) The protease domain of the constitutive homodimeric caspase-9 (residues 140-416) exhibits a similar level of catalytic activity as the apoptosome caspase-9 holoenzyme. The physiological substrate caspase-3 (C163A) was used in the assays. (C) The catalytic activities of the caspase-9 variants were examined using the fluorogenic substrate Ac-LEHD-AFC.
suppresses the proteolytic activity of caspase-9, and the linker sequence preceding the protease domain further augments the suppression. Thus, at least one compelling reason for assembly of the central CARD complex is to move the CARD and the linker sequences away from the protease domain of caspase-9. Despite the removal of the CARD and the linker sequences, the catalytic activity of caspase-9 (residues 140-416) is still only a fraction of that by WT caspase-9 in the presence of the apoptosome. Thus, the apoptosome must have another role in the activation of caspase-9. Elucidation of this role may require structural information on the protease domain of caspase-9 in the holoenzyme. Unfortunately, the protease domain of caspase-9 remains invisible in the EM density maps. This could be because of either its intrinsic property (no interaction with the apoptosome platform or the CARD complex) or disruption of such transient interactions involving the protease domain. In the former scenario, the protease domain of caspase-9 is left with literally only one choice: activation through homodimerization. In the latter scenario, how to capture the transient interactions remains a daunting task that, given the intensity of unsuccessful structural investigations, may have to be addressed by single-molecule biophysical studies.
In this study, we show that an engineered, constitutively homodimeric caspase-9 exhibits robust catalytic activity (Fig. 5  A-C) . The catalytic activity of DC9 is significantly higher than that in a previous report (22) . This difference is likely a result of the different temperatures under which caspase-9 activity is examined. DC9 exhibits excellent solution behavior at 22°C (assay temperature in this study) but is prone to precipitation at 37°C [assay temperature of the previous study (22) ]. Remarkably, with deletion of the CARD and the linker sequences, DC9 (residues 140-416) has a higher catalytic activity than the apoptosomecaspase-9 holoenzyme. Thus, it is possible that, in addition to relieving the inhibition of C9CARD, apoptosome serves to promote dimerization of the protease domain of caspase-9. Scrutiny of this hypothesis awaits further experimental evidence.
Materials and Methods
Protein Purification and Holoenzyme Assembly. Human Apaf-1 and WT caspase-9 were purified as described (16) . The holoenzyme was assembled in the presence of 1 mM dATP by incubating Apaf-1, equine CytC, and caspase-9 at a molar ratio of 1:2:2. The dimeric caspase-9 was generated as described (22) .
EM. Cryo-EM images were recorded manually on an FEI Tecnai Polara electron microscope operating at 300 kV. The 26 movie frames of each micrograph were aligned by whole-image motion correction (23) . Contrast transfer function parameters were estimated by CTFFIND4 (24) , and 2D and 3D classifications were carried out using RELION (version 1.4-alpha) (25) . The particle-polishing approach was applied (26) . Reported resolutions are based on Fourier Shell Correlation (FSC) curves between independently refined half-maps, using the 0.143 criterion (27) . The resulting maps from refinement were postprocessed by RELION and sharpened by a negative B-factor (28) . Local resolution variations were estimated using ResMap (29) . The structures of Apaf-1 apoptosome (PDB code 3JBT) (16) and 2:1 ApCARD-C9CARD complex (PDB code 4RHW) (17) were docked into the overall maps by COOT (30) and fitted into density by CHIMERA (31) .
Analysis of Interactions Between Apaf-1 and Caspase-9. For apoptosome assembly, Apaf-1 mutants were individually incubated with equine CytC at a molar ratio of 1:2 in the presence of 1 mM dATP. For holoenzyme assembly, the apoptosome mutants were individually incubated with WT caspase-9 at a molar ratio of 4:1.
Caspase-9 Activity Assay. The effect of Apaf-1 mutations on caspase-9 activity was measured using caspase-3 (C163A) and Ac-LEHD-AFC. The molar ration between Apaf-1 and caspase-9 is 5:1. The assay was performed as described (8) . The basal activities of caspase-9 truncations were also measured as described (8) .
